1. 285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors. (10th December 2020) Authors: Hong, David; Butler, Marcus; Pachynski, Russell; Sullivan, Ryan; Kebriaei, Partow; Boross-Harmer, Sarah; Frigault, Matthew; Dumbrava, Ecaterina; Sauer, Amy; Brophy, Francine; Navenot, Jean-Marc; Fayngerts, Svetlana; Bai, Jane; Norry, Elliot; Fracasso, Paula Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A174 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors. (9th November 2020) Authors: Hong, David; Butler, Marcus; Pachynski, Russell; Sullivan, Ryan; Kebriaei, Partow; Boross-Harmer, Sarah; Frigault, Matthew; Dumbrava, Ecaterina; Sauer, Amy; Brophy, Francine; Navenot, Jean-Marc; Fayngerts, Svetlana; Bai, Jane; Norry, Elliot; Fracasso, Paula Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗